IgM Anti-Ganglioside Antibodies Induced by Melanoma Cell Vaccine Correlate with Survival of Melanoma Patients

This publication has 18 references indexed in Scilit:

• Approaches to Augmenting the Immunogenicity of Melanoma Gangliosides: From Whole Melanoma Cells to Ganglioside‐KLH Conjugate Vaccines
  Immunological Reviews, 1995
• A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma
  European Journal Of Cancer, 1995
• Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine
  Annals of Surgery, 1992
• Antibody responses to ganglio-series gangliosides in different strains of inbred mice
  Molecular Immunology, 1992
• HUMAN MONOCLONAL ANTIBODY TO GANGLIOSIDE GM2 FOR MELANOMA TREATMENT
  The Lancet, 1989
• Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2.
  Proceedings of the National Academy of Sciences, 1986
• Longitudinal data analysis using generalized linear models
  Biometrika, 1986
• Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma.
  Proceedings of the National Academy of Sciences, 1985
• Gangliosides of normal and neoplastic human melanocytes
  Biochemical and Biophysical Research Communications, 1984
• Human antibody to OFA-I, a tumor antigen, produced in vitro by Epstein-Barr virus-transformed human B-lymphoid cell lines.
  Proceedings of the National Academy of Sciences, 1982